亨廷顿病的治疗策略:目前的方法和未来的方向
Mehak Gulzar1, Sana Kauser2, Sumaiya Khan1
1Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India.
Neurodegenerative disease management
|August 28, 2025
概括
亨廷顿病 (HD) 治疗正在推进,重点是通过基因疗法和小分子降低突变亨廷丁 (mHTT) 水平. 需要进一步的研究来克服分娩和安全方面的挑战,以改善患者的治疗结果.
科学领域:
- 神经科学
- 遗传学
- 药理学
背景情况:
- 亨廷顿病 (HD) 是一种渐进的遗传性神经退行性疾病.
- 它源于亨廷顿基因的CAG三核酸扩张,导致毒性突变亨廷丁 (mHTT) 在大脑中积累.
- 疾病表现为运动,认知和精神障碍.
研究的目的:
- 对亨廷顿病的治疗策略进行审查.
- 探索包括小分子,基因疗法和蛋白质降解技术在内的新方法.
- 评估像VTX-003和ANX005这样的特定药物的潜力.
主要方法:
- 现有HD治疗研究的文献综述.
- 分析小分子方法,基因疗法 (例如基于CRISPR) 和蛋白质降解技术.
- 评估针对减少mHTT的新兴疗法.
主要成果:
- 多种治疗策略有望降低mHTT水平.
- 基于CRISPR的方法和小分子向蛋白质降解是开发的关键领域.
- 目前正在研究VTX- 003和ANX005是否有可能减缓疾病的进展.
结论:
- 在开发亨廷顿病治疗方面取得了显著进展.
- 长期有效性,药物输送和尽量减少非目标效应仍然是挑战.
- 加强治疗干预对于改善患者生活质量至关重要.
相关概念视频
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Parkinson's Disease: Treatment
376
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
376
Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
Treatment Strategies for Psychological Disorders
267
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
267
Drug Therapy
96
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
96
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666


